Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02662569 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT02662569 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 986 participants.
The verdict
NCT02662569, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemia.
Interventions
- OTHER Placebo
- DRUG Atorvastatin
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2017-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02662569
The ClinicalTrials.gov registry entry for NCT02662569 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 986 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02662569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02662569 about?
NCT02662569 is a clinical study titled "Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia". The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in diabetic adults with hyperlipidemia or mixed dyslipidemi...
What is the current status of trial NCT02662569?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2016-04-14. Estimated completion is 2017-12-06.
What interventions are being tested in trial NCT02662569?
The interventions under investigation include: Placebo (OTHER), Atorvastatin (DRUG), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02662569?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.